title: BCG vaccination status may predict sputum conversion in patients with pulmonary tuberculosis: a new consideration for an old vaccine?
abstract: BACKGROUND
  Failure to convert (persistent sputum and/or culture positivity) while on antituberculosis (anti-TB) treatment at the end of the second month of anti-TB therapy has been reported to be a predictor of treatment failure. Factors that could be associated with persistent bacillary positivity at the end of the second month after initiation of anti-TB treatment were assessed.
  
  
  METHODS
  A prospective cohort study was conducted in 754 patients with sputum culture positive pulmonary TB in Mwanza, Tanzania. Information on social demographic characteristics, anthropometric measurements, BCG scar status, HIV status, CD4+ count, white blood cell count, haemoglobin and sputum culture status was obtained.
  
  
  RESULTS
  Factors associated with sputum culture non-conversion at the end of the second month of anti-TB treatment were initial acid-fast bacilli (AFB) culture grading of 3+ (OR 5.70, 95% CI 1.34 to 24.31, p=0.02) and absence of a BCG scar (OR 3.35, 95% CI 1.48 to 7.58, p=0.004).
  
  
  CONCLUSIONS
  Patients with pulmonary TB with no BCG scar and high initial AFB sputum intensity are at risk of remaining sputum culture positive at the end of the second month of anti-TB treatment. These findings reflect a beneficial role for BCG vaccination on sputum conversion which should also be examined in large studies in other areas. The finding of a beneficial role for BCG vaccination on the treatment of pulmonary TB is important for TB control and vaccination programmes.
authors.affiliation: The Gade Institute, Section for Microbiology and Immunology, University of Bergen, Department of Microbiology and Immunology, Haukeland University Hospital, Norway .
authors.forename: Kidola
authors.initials: K
authors.lastname: Jeremiah
authors.forename: George
authors.initials: G
authors.lastname: Praygod
authors.forename: Daniel
authors.initials: D
authors.lastname: Faurholt-Jepsen
authors.forename: Nyagosya
authors.initials: N
authors.lastname: Range
authors.forename: Aase B
authors.initials: AB
authors.lastname: Andersen
authors.forename: Harleen M S
authors.initials: HM
authors.lastname: Grewal
authors.forename: Henrik
authors.initials: H
authors.lastname: Friis
mesh_terms: D000276:Adjuvants, Immunologic; D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D001500:BCG Vaccine; D018791:CD4 Lymphocyte Count; D002921:Cicatrix; D024881:Drug Resistance, Bacterial; D005260:Female; D006678:HIV / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification*; D011446:Prospective Studies; D017678:Sex Distribution; D013183:Sputum / Q000382:microbiology*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000382:microbiology* / Q000517:prevention & control; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine